Sökning: onr:"swepub:oai:DiVA.org:uu-347411" >
Two decades of high...
Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer
-
- Åström, Lennart (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Grusell, Erik (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap,The Svedberg-laboratoriet
-
- Sandin, Fredrik (författare)
- Regional Cancer Center Uppsala-Örebro (RCC), Uppsala, Sweden
-
visa fler...
-
- Turesson, Ingela (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Holmberg, Lars (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Kings Coll London, Fac Life Sci & Med, London, England
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2018
- 2018
- Engelska.
-
Ingår i: Radiotherapy and Oncology. - : Elsevier BV. - 0167-8140 .- 1879-0887. ; 127:1, s. 81-87
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: High-dose-rate brachytherapy (HDR-BT) has optimal prerequisites in radiotherapy of prostate cancer (PC) with a conformal dose distribution and high doses per fraction giving a biological dose escalation. We report the outcome after HDR-BT and external beam radiotherapy (EBRT) after 20 years of experience.Material and methods: The study includes 623 patients, median age of 66 years, treated from 1995 to 2008 and a median follow up of 11 years (range 2–266 months). Androgen deprivation therapy was given to 429 patients (69%). The HDR-BT was given with two 10 Gy fractions and the EBRT with 2 Gy fractions to 50 Gy.Results: The 10-year PC-specific survival was 100%, 92%, 91%, and 75% for low-, intermediate-, high- and very high-risk patients respectively, and the 10-year probability of PSA relapse was 0%, 21%, 33%, and 65% respectively. The 10-year actuarial prevalence for ≥grade 2 GU- and GI-toxicities were 28% and 12% respectively and for ≥grade 3, 4% and 1% respectively. Urethral stricture was the most frequent GU complication with a 10-year actuarial incidence of 10%. Treatment without dose constraints for the urethra conferred a higher incidence 18%, compared to 5% after 2003 (p < 0.001). Sixteen patients experienced grade 4 GU toxicity, of which 13 were treated before 2003. No grade 4 rectal toxicity was seen.Conclusion: The combination of EBRT and HDR-BT with adequate dose constraints to risk organs provides satisfactory long-term tumour control even in high-risk patients. GI toxicity stabilised but GU toxicity progressed during the 10-year follow up.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Brachytherapy
- High dose rate
- Prostate cancer
- Radiotherapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas